Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | PRF1 | P14222 | 5/20 | 0.49 |
| ▸ | GRM5 | P41594 | 4/20 | 0.49 |
| ▸ | GSK3B | P49841 | 3/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952603 | 1.00 | CA12 (0.50) | CA12CA9PRF1GRM5GSK3B | |
| SCHEMBL2014718 | 0.86 | PRF1 (0.61) | CA12CA9PRF1GRM5GSK3B | |
| SCHEMBL29950887 | 0.85 | CLK4 (0.53) | CA12CA9PRF1GRM5GSK3B | |
| SCHEMBL26119392 | 0.85 | CLK4 (0.53) | CA12CA9PRF1GRM5GSK3B | |
| SCHEMBL28697772 | 0.84 | PRF1 (0.51) | CA12CA9PRF1GRM5GSK3B | |
| SCHEMBL2017969 | 0.82 | PRF1 (0.64) | CA12CA9PRF1GRM5GSK3B | |
| SCHEMBL3946742 | 0.82 | PARP10 (0.60) | GRM5PARP1 | |
| SCHEMBL25042822 | 0.80 | PRF1 (0.45) | CA12CA9PRF1GRM5GSK3B | |
| SCHEMBL618639 | 0.73 | CA12 (0.53) | CA12CA9PRF1GRM5GSK3B | |
| SCHEMBL164795 | 0.73 | GRM5 (0.68) | CA12CA9PRF1GRM5GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3759075-B1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | FERRO THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-118488946-A | IKAROS zinc finger family degradation agent and application thereof | 吉利德科学公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-113912601-B | Novel imidazo [1,2-a ] pyridine derivatives, preparation method and medical application thereof | 上海拓界生物医药科技有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| CN-115413275-A | Substituted 1,1 , -biphenyl compounds and methods of use thereof | 爱彼特生物制药公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-113912601-A | Novel imidazo [1,2-a ] pyridine derivatives, preparation method and medical application thereof | 上海拓界生物医药科技有限公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-112041301-A | Compounds having iron death inducing activity and methods of use thereof | 费罗治疗公司 | 2020-12-04 | — | — | CN | disclosed |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | MOLECULAR SKIN THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| EP-3197879-A1 | NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | Almirall S.A. (ES) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046390-A1 | NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2016-03-31 | — | — | WO | disclosed |
| CN-101309690-A | Chemokine receptor binding compounds | ANORMED INC (CA) | 2008-11-19 | — | — | CN | disclosed |
| EP-1924265-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | Genzyme Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | CA12 1648/4885CA9 1906/4885PRF1 2407/4885 |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | AIFM2, GPX4, GPX1 | CA12 1488/4885CA9 1637/4885PRF1 2673/4885 |
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | CA12 3269/4885CA9 3937/4885PRF1 447/4885 |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | CA12 3741/4885CA9 2261/4885PRF1 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.